Sentiment-Signal
27,9
Bearisch
Composite Score (0–100)
Insider (25%)
8.9
1 Insider, 580K $ Volumen
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Unternehmen & Branche
| Name | AbCellera Biologics Inc. |
|---|---|
| Ticker | ABCL |
| CIK | 0001703057 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,25 Mrd. USD |
| Beta | 0,85 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 75,128,000 | -146,412,000 | -0.49 | 1,356,950,000 | 966,904,000 |
| 2025-09-30 | 10-Q | 8,955,000 | -57,119,000 | -0.19 | 1,355,992,000 | 964,038,000 |
| 2025-06-30 | 10-Q | 17,084,000 | -34,727,000 | -0.12 | 1,402,061,000 | 1,007,076,000 |
| 2025-03-31 | 10-Q | 4,235,000 | -45,621,000 | -0.15 | 1,344,208,000 | 1,022,982,000 |
| 2024-12-31 | 10-K | 28,833,000 | -162,857,000 | -0.55 | 1,360,553,000 | 1,056,084,000 |
| 2024-09-30 | 10-Q | 6,507,000 | -51,107,000 | -0.17 | 1,392,828,000 | 1,078,094,000 |
| 2024-06-30 | 10-Q | 7,323,000 | -36,930,000 | -0.13 | 1,412,481,000 | 1,110,968,000 |
| 2024-03-31 | 10-Q | 9,954,000 | -40,610,000 | -0.14 | 1,463,096,000 | 1,129,913,000 |
| 2023-12-31 | 10-K | 38,025,000 | -146,398,000 | -0.51 | 1,488,094,000 | 1,152,318,000 |
| 2023-09-30 | 10-Q | 6,599,000 | -28,610,000 | -0.10 | 1,512,190,000 | 1,182,775,000 |
| 2023-06-30 | 10-Q | 10,056,000 | -30,528,000 | -0.11 | 1,537,166,000 | 1,194,827,000 |
| 2023-03-31 | 10-Q | 12,192,000 | -40,110,000 | -0.14 | 1,497,919,000 | 1,208,500,000 |
| 2022-12-31 | 10-K | 485,424,000 | 158,519,000 | 0.50 | 1,540,907,000 | 1,233,277,000 |
| 2022-09-30 | 10-Q | 101,383,000 | 26,624,000 | 0.08 | 1,552,409,000 | 1,250,172,000 |
| 2022-06-30 | 10-Q | 45,917,000 | -6,785,000 | -0.02 | 1,593,784,000 | 1,212,856,000 |
| 2022-03-31 | 10-Q | 316,581,000 | 168,573,000 | 0.54 | 1,592,289,000 | 1,207,507,000 |
| 2021-12-31 | 10-K | 375,203,000 | 153,464,000 | 0.48 | 1,318,569,000 | 1,025,733,000 |
| 2021-09-30 | 10-Q | 5,508,000 | -21,380,000 | -0.08 | 1,172,732,000 | 953,397,000 |
| 2021-06-30 | 10-Q | 27,643,000 | -2,323,000 | -0.01 | 1,151,856,000 | 967,679,000 |
| 2021-03-31 | 10-Q | 202,741,000 | 117,221,000 | 0.37 | 1,128,523,000 | 957,124,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-27 | Booth Andrew | Officer, Chief Financial Officer | Open Market Purchase | 42,600 | 3.42 | 145,692.00 | +56,3% | |
| 2026-02-27 | Thermopylae Holdings Ltd. | 10% Owner | Open Market Purchase | 38,000 | 3.44 | 130,720.00 | +50,5% | |
| 2026-02-26 | Thermopylae Holdings Ltd. | 10% Owner | Open Market Purchase | 177,457 | 3.27 | 580,284.39 | +224,2% | |
| 2025-11-26 | Montalbano John S. | Director | Open Market Purchase | 50,000 | 3.57 | 178,460.00 | +69,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.